Search | Clinical Trials Finder

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Neoplasms, Head and Neck
Interventions: Dostarlimab, Belrestotug, Nelistotug, Remzistotug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: Pembrolizumab, Nivolumab; Drug
Lead sponsor: Hookipa Biotech GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more

Conditions: Neoplasms
Interventions: BI 765179, Ezabenlimab, Pembrolizumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more

Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Interventions: Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions: rezatapopt, pembrolizumab; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 33
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 27 more

Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2); Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Los Angeles, California + 25 more

Conditions: Colorectal Cancer
Interventions: favezelimab/pembrolizumab, regorafenib, TAS-102; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
Interventions: Durvalumab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Shirish M Gadgeel; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HLA-A2 Positive Cells Present, Refractory Melanoma
Interventions: Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Melanoma
Interventions: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: INBRX-106, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 22 more

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab Emtansine, Atezolizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Redlands, California

Conditions: Cervical Cancer
Interventions: Tiragolumab, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Irvine, California • Augusta, Georgia + 1 more

Conditions: Uveal Melanoma
Interventions: Tebentafusp; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: HER2-positive Breast Cancer
Interventions: Atezolizumab, Paclitaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer, Cervical Cancer
Interventions: PRGN-2009, M7824, EKG, CT Scan, Brain MRI, Biopsy; Biological · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions: MT-6402; Drug
Lead sponsor: Molecular Templates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more

Conditions: Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Interventions: MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Yuma, Arizona • Duarte, California + 32 more

Conditions: Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions: Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab; Drug · Biological
Lead sponsor: Intima Bioscience, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Duarte, California • Minneapolis, Minnesota

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Conditions: HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions: Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more

Conditions: Non-small Cell Lung Cancer
Interventions: NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg; Device · Drug
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 20 more

Search by objective public record fields.

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

CISH Inactivated TILs in the Treatment of NSCLC

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer